NRG Oncology Trial Finds No Difference in NeurocoNRG Oncology trial finds no difference in neurocognitive outcomes, but improved overall survival with stereotactic radiosurgery for SCLC brain metastases
Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC
Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC
Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer - EurekAlert!
FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC - EurekAlert!
PSMA PET/CT prior to salvage radiotherapy improves overall survival for prostate cancer patients: Real-world data from an entire country - EurekAlert!
Cell therapy improves overall survival of patients with colorectal cancer - EurekAlert!
New drug combination increases overall survival in patients with PIK3CA-mutated advanced breast cancer - EurekAlert!
Overall survival and quality-of-life superiority in modern phase 3 oncology trials - EurekAlert!
First-line treatment with dual-targeted therapies and chemotherapy doubles overall survival in patients with BRAF-mutated metastatic colorectal cancer - EurekAlert!
Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer - EurekAlert
